Dec 22, 2022 8:00 am EST Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
Nov 7, 2022 4:15 pm EST Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
Sep 29, 2022 9:00 am EDT Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
Sep 14, 2022 4:15 pm EDT Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference
Sep 13, 2022 8:00 am EDT Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
Sep 12, 2022 9:00 am EDT Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference